Asia Pacific ePRO, ePatient Diaries, and eCOA Market

Market Introduction

The usage of electronic Clinical Outcome Assessment (eCOA) is a push towards adapting to the ‘new normal’ as it is a method to gather patient data electronically through the use of technology such as smart home devices, handheld monitors, wearables, e-diaries, tablets and web servers to allow the stakeholders in the trials (patients, healthy volunteers, investigators and caregivers) to report outcomes directly and digitally. Although historically COA was only related to the evaluation of Patient-Related Outcomes (PRO), the FDA has now broadened the definition to include PerfO, ClinRO and ObsRO along with PRO. In simple terms, when the above parameters are reported electronically, they fit under the eCOA spectrum.

eCOA/ePRO platform has substantial benefits for sponsors and CROs, as it reduces administrative burden, mitigates cost, and speeds trials. Such a system shows strong results with fewer errors and discrepancies, improved data quality, clearer signals, and standardized, accurate studies. The increasing adoption of EHR, and government regulations mandating maintain health records is driving the growth of the market.

Thus, a growing demand for clinical trials is expected to create a significant demand for ePRO, ePatient Diaries, and eCOA in the coming years, which is further anticipated to drive the ePRO, ePatient Diaries, and eCOA market.

The DIA China Digital Health Community organized a series of Remote Digital Clinical Trials During COVID-19 Pandemic online seminars to increase global interest in remote clinical trials and digital clinical trial resources. Veteran clinicians and researchers presented real-life examples of remote clinical trial and digital trial technology implementations in China and strategies and plans based on their experiences. Sponsors and CROs have been able to preserve their business continuity in China by using remote clinical trials to overcome the difficulties of conducting conventional clinical trials faced by the COVID-19 pandemic (impacting on-site subject visits, data monitoring, and drug delivery). However, since these trials are just getting underway in China, it's important to optimize the effect of these technologies and services, and relevant regulations should evolve to support these developments accordingly. Thus, ePRO, e-Patient Diaries, and eCOA market is moderately impacted due to COVID -19.

Asia Pacific ePRO, ePatient Diaries, and eCOA Strategic Insights

Strategic insights for the Asia Pacific ePRO, ePatient Diaries, and eCOA provides data-driven analysis of the industry landscape, including current trends, key players, and regional nuances. These insights offer actionable recommendations, enabling readers to differentiate themselves from competitors by identifying untapped segments or developing unique value propositions. Leveraging data analytics, these insights help industry players anticipate the market shifts, whether investors, manufacturers, or other stakeholders. A future-oriented perspective is essential, helping stakeholders anticipate market shifts and position themselves for long-term success in this dynamic region. Ultimately, effective strategic insights empower readers to make informed decisions that drive profitability and achieve their business objectives within the market.

Asia Pacific ePRO, ePatient Diaries, and eCOA Report Scope

Asia Pacific ePRO, ePatient Diaries, and eCOA Regional Insights

The geographic scope of the Asia Pacific ePRO, ePatient Diaries, and eCOA refers to the specific areas in which a business operates and competes. Understanding local distinctions, such as diverse consumer preferences (e.g., demand for specific plug types or battery backup durations), varying economic conditions, and regulatory environments, is crucial for tailoring strategies to specific markets. Businesses can expand their reach by identifying underserved areas or adapting their offerings to meet local demands. A clear market focus allows for more effective resource allocation, targeted marketing campaigns, and better positioning against local competitors, ultimately driving growth in those targeted areas.

The ePRO, ePatient Diaries, and eCOA market in Asia Pacific is expected to grow from US$ 348.8 million in 2021 to US$ 964.2 million by 2028; it is estimated to grow at a CAGR of 15.6% from 2021 to 2028. Increasing number of smartphone users is likely to boost the ePRO, e-Patient Diaries, and eCOA's adoption in the coming years. Mobile-enabled portals make it easier for patients to communicate with healthcare providers and allow patients to check test results, and review their medical record using smartphones. Also, market players are launching products for mobile applications, which will further boost the market's growth. For instance, in December 2020, Mednet, a healthcare technology company, announced its latest software release featuring expanded electronic patient reported outcomes (ePRO) capabilities. The new ePRO module is designed to increase patient engagement and enable remote participation, an increasingly important requirement in the COVID-19 era, while significantly improving the user experience for clinical staff as well as study participants. The new Mednet module is the result of a year-long development process designed to improve the user experience of Mednet's ePRO capability, including fully optimized module for mobile tablets. Also, in Nov 2020, Medable launched telehealth eCOA technology, which reportedly enables outcome assessment to be conducted remotely via web and mobile.

Key Market Segments

In terms of type of solution, the e-clinical outcome assessments segment accounted for the largest share of the Asia Pacific ePRO, ePatient Diaries, and eCOA market in 2020. In terms of modality, the mobile devices segment held a larger market share of the ePRO, ePatient Diaries, and eCOA market in 2020. In terms of end user, the cinical trial sponsors segment held a larger market share of the ePRO, ePatient Diaries, and eCOA market in 2020.

Major Sources and Companies Listed

A few major primary and secondary sources referred to for preparing this report on the EPRO, ePatient Diaries, and eCOA market in Asia Pacific are company websites, annual reports, financial reports, national government documents, and statistical database, among others. Major companies listed in the report are ERT Clinical, ArisGlobal LLC, The Diary Pte. Ltd, ICON PLC, PAREXEL INTERNATIONAL CORPORATION, Anju Software, Inc., Kayentis, Bracket Global LLC, Dassault Systèmes SE, and CRF Health.

Reasons to buy report

• To understand the Asia Pacific ePRO, ePatient Diaries, and eCOA market landscape and identify market segments that are most likely to guarantee a strong return
• Stay ahead of the race by comprehending the ever-changing competitive landscape for Asia Pacific ePRO, ePatient Diaries, and eCOA market
• Efficiently plan M&A and partnership deals in Asia Pacific ePRO, ePatient Diaries, and eCOA market by identifying market segments with the most promising probable sales
• Helps to take knowledgeable business decisions from perceptive and comprehensive analysis of market performance of various segment form Asia Pacific ePRO, ePatient Diaries, and eCOA market
• Obtain market revenue forecast for market by various segments from 2021-2028 in Asia Pacific region.

ASIA PACIFIC EPRO, EPATIENT DIARIES, AND ECOA MARKET SEGMENTATION

By Type of Solution

• eClinical Outcome Assessments
• e-Patient Reported Outcomes
• Clinician Reported Outcomes
• Observer Reported Outcomes
• Performance Outcomes
• e-Patient Diaries

By Modality

• Computer
• Mobile Devices

By End User

• Clinical Trial Sponsors
• Contract Research Organizations
• Hospitals
• Academic Institutes
• Pharmaceutical Companies
• Others

By Country

• Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Rest of Asia Pacific

Companies Mentioned

1. ERT Clinical             
2. ArisGlobal LLC       
3. The Diary Pte. Ltd                
4. ICON PLC                
5. PAREXEL INTERNATIONAL CORPORATION   
6. Anju Software, Inc.             
7. Kayentis                  
8. Bracket Global LLC              
9. Dassault Systèmes SE        
10. CRF Health